Efficacy of a two-component acellular pertussis vaccine in infants

Pediatric Infectious Disease Journal

Volumn 16, Issue 11, 1997, Pages 1038-1044

  Liese, Johannes G ^a   Meschievitz, Carlton K ^b   Harzer, Erika ^c   Froeschle, James ^b   Hosbach, Phil ^b   Hoppe, Jörg E ^d   Porter, Frank ^a   Stojanov, Silvia ^a   Niinivaara, Kii ^a   Walker, Alexander M ^e   Belohradsky, Bernd H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Pasteur Merieux Connaught   (United States)

^c SanofiPasteur MSD   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Acellular pertussis vaccine; Case control study; Pertussis; Vaccine efficacy; Vaccine safety; Whole cell pertussis vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; DIPHTHERIA TOXOID; DPT IMPFSTOFF; DT IMPFSTOFF; PERTUSSIS VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM CULTURE; BORDETELLA PERTUSSIS; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INFANT; MAJOR CLINICAL STUDY; PERTUSSIS; PRIORITY JOURNAL; RISK FACTOR;

CASE-CONTROL STUDIES; HUMANS; INFANT; PERTUSSIS VACCINE; PROSPECTIVE STUDIES; RISK FACTORS; VACCINATION;

EID: 0030696639     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199711000-00007     Document Type: Article

References (30)

1. CDC. Pertussis: United States, January 1992-June 1995. MMWR 1995;44:522-29.
2. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981;68:650-60.
3. Howson CP, Howe CJ, Fineberg HV. Adverse effects of pertussis and rubella vaccines: a report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. Washington, DC: National Academy Press, 1991.
4. Schmitz M, Wassilak SGF, Schulte-Wissermann H, Wirsing von König CH. Schätzung zur Pertussisinzidenz am linken Niederrhein. Monatsschr Kinderheilkd 1994;142:41-4.
5. Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1984;1:122-6.
6. Kimura M, Kuno-Sakai H. Pertussis vaccines in Japan. Acta Paediatr Jpn 1988;30:143-53.
7. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995;96:548-57.
8. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995;96:557-66.
9. Pittmann M. Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough: a hypothesis. Rev Infect Dis 1979;1:402-12.
10. Pichichero ME, Francis AB, Blatter MM, et al. Acellular pertussis vaccination of 2-month-old infants in the United States. Pediatrics 1992;89:882-7.
11. Bernstein HH, Rothstein EP, Pichichero ME, et al. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4-through 6-year old U. S. children. Am J Dis Child 1992;146:556-9.
12. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet 1988;1:995-1060.
13. Loughlin AM, Marchant CD, Lett S, Shapiro ED. Efficacy of Haemophilus influenzae type b vaccines in Massachusetts children 18 to 59 months of age. Pediatr Infect Dis J 1992; 11:374-9.
14. Shapiro ED, Murphy TV, Wald ER. The protective efficacy of Haemophilus b polysaccharide vaccine. JAMA 1988;260: 1419-22.
15. Wenger JD, Pierce R, Deaver KA, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US. children aged 18-59 months. Lancet 1991;338:395-8.
16. Liese JG, Hoppe JE, Stefans G, Müller A, Belohradsky BH. Pertussisdiagnostik durch Erregerisolierung mittels Direktausstrich von Nasopharyngealabstrichen. Monatsschr Kinderheilkd 1994;142:967-70.
17. Hoppe JE, Schwaderer J. Direct plating versus use of transport medium for detection of Bordetella species from nasopharyngeal swabs. Eur J Clin Microbiol Infect Dis 1989;8: 264-5.
18. WHO meeting on case definition of pertussis: Geneva, 10-11 January, 1991. Document MIN/EPI/PERT/91.1 1991:4-5.
19. Comstock GW. Evaluating vaccination efficacy and vaccine efficacy by means of case-control studies. Epidemiol Rev 1994;16:77-89.
20. Storsaeter J, Hallander H, Farrington CP, Olin P, Möllby R, Miller E. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 1990;8:457-61.
21. Blackwelder WC, Storsaeter J, Olin P, Hollander HO. Acellular pertussis vaccines: efficacy and evaluation of clinical case definitions. Am J Dis Child 1991;145:1285-9.
22. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341-8.
23. Plotkin SA, Cadoz M. The acellular pertussis vaccine trials: an interpretation. Pediatr Infect Dis J 1997;16:508-17.
24. Olin P. Commentary: the best acellular pertussis vaccines are multicomponent. Pediatr Infect Dis J 1997;16:517-9.
25. Edwards KM, Decker MD. Acellular pertussis vaccines for infants. N Engl J Med 1996;334:391-2.
26. Schneerson R, Robbins JB, Taranger J, Lagergård T, Trollfors B. A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned. Lancet 1996;348:1289-92.
27. Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;333:1045-50.
28. Schmitt HJ, Wirsing von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41.
29. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55.
30. Edwards KM, Decker MD. Challenges for licensure of new diphtheria, tetanus toxoid, acellular pertussis combination vaccines: counterpoint. Pediatr Infect Dis J 1996;15:1070-3.